Work

20P Evolution of early-stage ERBB2-mutant, HER2+ breast cancer under neoadjuvant therapy

Year: 2025

Type: article

Abstract: ERBB2 mutations, present in 2–5% of breast cancers but their evolution under HER2-targeted therapies remains unclear. We characterized the molecular dynamics of ERBB2-mutant tumors in the randomized PREDIX HER2 trial, comparing neoadjuvant trastuzumab emtansine (T-DM1) with dual HER2 blockade and chemotherapy in early HER2-positive breast cancer.

Source: ESMO Open

DOI: 10.1016/j.esmoop.2025.104574